- Fireside Chat May 2, 2023 from 10:00 – 10:30 AM ET - PRINCETON, N.J. --(BUSINESS WIRE)--Apr. 25, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will
Reported JELMYTO® full year 2022 net product revenues of $64.4 million , an increase of 34% from full year 2021 Completed enrollment of the ENVISION Phase 3 pivotal clinical trial for UGN-102 for LG-IR-NMIBC Topline data readout from ATLAS clinical study and Complete Response from ENVISION pivotal
Conference Call and Webcast Scheduled for Thursday, March 16, 2023 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 9, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 6, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new
PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 1, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March:
--In a Small Feasibility Study, UGN-102 Achieves a Complete Response in 75% (6 of 8) Patients --UGN-102 is Being Studied in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 15, 2023-- UroGen Pharma Ltd.
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 11, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization
--If approved, UGN-102 would be the first non-surgical primary therapeutic to treat a subset of bladder cancer characterized by high recurrence rates and multiple surgeries PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 19, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to
PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 9, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 12 new
-- Results from this ongoing, noninterventional rollover study were presented at the 23 rd Annual Society of Urological Oncology (SUO) Meeting in San Diego SAN DIEGO --(BUSINESS WIRE)--Dec. 2, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing